Menu
Search
|

Menu

Close
X

Vanda Pharmaceuticals Inc VNDA.OQ (NASDAQ Stock Exchange Global Market)

17.30 USD
-- (--)
As of Feb 20
chart
Previous Close 17.30
Open --
Volume --
3m Avg Volume 136,138
Today’s High --
Today’s Low --
52 Week High 18.95
52 Week Low 11.90
Shares Outstanding (mil) 44.93
Market Capitalization (mil) 777.25
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY17
165
FY16
146
FY15
110
EPS (USD)
FY17
-0.349
FY16
-0.417
FY15
-0.942
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
4.71
8.67
Price to Book (MRQ)
vs sector
5.92
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
0.00
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
-10.55
13.57
Return on Equity (TTM)
vs sector
-11.85
15.19

EXECUTIVE LEADERSHIP

H. Thomas Watkins
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Mihael Polymeropoulos
President, Chief Executive Officer, Director, Since 2010
Salary: $618,000.00
Bonus: $1,483,200.00
James Kelly
Chief Financial Officer, Executive Vice President, Treasurer, Since 2017
Salary: $390,000.00
Bonus: $202,800.00
Gian Piero Reverberi
Senior Vice President, Chief Compliance Officer, Since 2016
Salary: $451,536.00
Bonus: $203,191.00
Richard Gulino
Senior Vice President, General Counsel, Secretary, Since 2015
Salary: $325,000.00
Bonus: $195,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2200 Pennsylvania Ave NW Ste 300
WASHINGTON   DC   20037-1754

Phone: +1202.7343400

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.

SPONSORED STORIES